1. Благосклонная Я.В., Шляхто Е.В., Бабенко А.Ю. Эндокринология. Учебник для медицинских вузов. СПб.: СпецЛит, 2004. 398 с.
2. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте. Методическое пособие для врачей. М., 2005.
3. Захаров В.В., Яхно Н.Н. Синдром умеренных когнитивных расстройств в пожилом и старческом возрасте // Рус. мед. журн. 2004. (10). 573–576.
4. Коберская Н.Н. Когнитивный потенциал Р300 // Неврол. журн. 2003. (6). 34-42.
5. Ameri A. The effects of cannabinoids on the brain // Prog. Neurobiol. 1999. 58. 315–348.
6. Bluher M., Engeli S., Kloting N. et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity // Diabetes. 2006. 55. 3053–3060.
7. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS // Annu. Rev. Neurosci. 2006. 29. 37–76.
8. Cota D., Woods S. The role of the endocannabinoid system in the regulation of energy homeostasis // Curr. Opin. Endocrinol. Diabetes. 2005. 12. 338–351.
9. Cote M., Matias I., Lemieux I. et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men // Int. J. Obes (Lond). 2007. 31. 692–699.
10. De Petrocellis L., Cascio M.G., Di Marzo V. The endocannabinoid system: a general view and latest additions // Br. J. Pharmacol. 2004. 141. 765–774.
11. Devane W.A., Hanus L., Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor // Science. 1992. 258. 1946–1949.
12. Di Marzo V., Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’ // Prostaglandins Leukot. Essent. Fatty Acids. 1995. 53. 1–11.
13. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance // Nat. Neurosci. 2005. 8. 585–589.
14. Frodl-Bauch T., Bottlender R., Hegerl U. Neurochemical substrates and neuroanatomical generators of the event-related P300 // Neuropsychobiology. 1999. 40. 86–94.
15. Gary-Bobo M., Elachouri G., Gallas J.F. et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa // Hepatology. 2007. 46. 122–129.
16. Hampson R.E., Deadwyler S.A. Role of cannabinoid receptors in memory storage // Neurobiol. Dis. 1998. 5. 474–482.
17. Hénon H., Pasquier F., Leys D. Poststroke dementia // Cerebrovasc. Dis. 2006. 22. 61–70.
18. Howlett A.C., Breivogel C.S., Childers S.R. et al. Cannabinoid physiology and pharmacology: 30 years of progress // Neuropharmacology. 2004. 47. (Suppl. 1). 345–358.
19. Idris A.I., van ‘t Hof R.J., Greig I.R. et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors // Nat. Med. 2005. 11. 774–779.
20. Jbilo O., Ravinet-Trillou C., Arnone M. et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance // FASEB J. 2005. 19. 1567–1569.
21. Johnson K.C., Margolis K.L., Espeland M.A. et al. A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women’s Health Initiative Memory Study // J. Am. Geriatr. Soc. 2008. 56. 1449–1458.
22. Lichtman A.H. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats // Eur. J. Pharmacol. 2000. 404. 175–179.
23. Matthews D., Hosker J., Rudenski A. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. 1985. 28. (7). 412–419.
24. Osei-Hyiaman D., DePetrillo M., Pacher P. et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity // J. Clin. Invest. 2005. 115. 1298–1305.
25. Pagotto U., Vicennati V., Pasquali R. The endocannabinoid system and the treatment of obesity // Ann. Med. 2005. 37. 270–275.
26. Piomelli D. The molecular logic of endocannabinoid signaling // Nat. Rev. Neurosci. 2003. 4. 873–884.
27. Polich J. Meta-analysis of P300 normative aging studies // Psychophysiology. 1996. 33. 334-353.
28. Polich J. Attention, probability and task demands as determinants of P300 latency from auditory stimuli // Electroencephalogr. Clin. Neurophysiol. 1986. 63. 251-259.
29. Reibaud M., Obinu M.C., Ledent C. et al. Enhancement of memory in cannabinoid CB1 receptor knock-out mice // Eur. J. Pharmacol. 1999. 379. R1–2.
30. Robinson L., McKillop-Smith S., Ross N.L. et al. Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats // Psychopharmacology (Berl). 2008. 198. 551-563.
31. Sim-Selley L. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids // Crit. Rev. Neurobiol. 2003. 15. 91–119.
32. Sugiura T., Kondo S., Sukagawa A. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain // Biochem. Biophys. Res. Commun. 1995. 215. 89–97.
33. Wang H., Dey S.K., Maccarrone M. Jekyll and Hyde: two faces of cannabinoid signaling in male and female fertility // Endocr. Rev. 2006. 27. 427–448.
34. Whitmer R.A., Gustafson D.R., Barrett-Connor E. et al. Central obesity and increased risk of dementia more than three decades later // Neurology. 2008. 71. 1057–1064.
35. Whitmer R.A., Gunderson E.P., Barrett-Connor E. et al. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study // BMJ. 2005. 330. 1360–1364.
36. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain // Science. 2002. 296. 678–682.
37. Wolff M.C., Leander J.D. SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task // Eur. J. Pharmacol. 2003. 477. 213–217.
